Provided by Tiger Trade Technology Pte. Ltd.

X4 Pharmaceuticals Inc

3.52
-0.0850-2.36%
Volume:1.45M
Turnover:5.29M
Market Cap:348.50M
PE:-3.96
High:3.68
Open:3.60
Low:3.44
Close:3.60
52wk High:4.83
52wk Low:2.80
Shares:99.15M
Float Shares:62.35M
Volume Ratio:6.98
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8867
EPS(LYR):-1.8726
ROE:-113.08%
ROA:-28.15%
PB:2.24
PE(LYR):-1.88

Loading ...

X4 Pharmaceuticals Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $12

THOMSON REUTERS
·
Jun 02

U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik

Reuters
·
Jun 02

BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Jun 02

X4 Pharmaceuticals grants 160,000 inducement stock options priced at $4.31 per share

Reuters
·
Jun 02

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 02

X4 Pharma to present at Jefferies Global Healthcare Conference

Reuters
·
May 27

X4 Pharmaceuticals corrects director nominee name in amended 8-K filing

Reuters
·
May 14

X4 Pharmaceuticals shareholders approved amended 2017 equity incentive plan share increase

Reuters
·
May 13

BRIEF-X4 Pharmaceuticals Inc - May Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or Units - SEC Filing

Reuters
·
May 07

X4 Pharmaceuticals Inc - May Offer up to $300 Mln of Common Stock, Preferred Stock, Debt Securities, Warrants, and/or Units - SEC Filing

THOMSON REUTERS
·
May 07

X4 Pharmaceuticals net loss widens to $20.2 million in Q1 FY26; revenue drops to $2.7 million

Reuters
·
May 06

BRIEF-X4 Pharmaceuticals Q1 EPS USD -0.16

Reuters
·
May 06

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 06

X4 Pharmaceuticals Q1 Operating Expenses USD 23.014 Million

THOMSON REUTERS
·
May 06

X4 says EU approves Xolremdi for WHIM syndrome treatment

Reuters
·
Apr 29

X4 Pharmaceuticals Announces European Commission Approval of Xolremdi® (Mavorixafor), the First and Only Authorized Treatment for Patients With Whim Syndrome in the European Union

THOMSON REUTERS
·
Apr 29

X4 Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Apr 27

BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 02

X4 Pharmaceuticals issues inducement stock options for 32,000 shares to new hires

Reuters
·
Apr 02

X4 Pharmaceuticals Inc. Announces Annual Stockholders Meeting Notice

Reuters
·
Mar 20